Rasmussen, T. A., Jørgensen, M., Bjerrum, S.
, Jensen-Fangel, S., Støvring, H., Østergaard, L. J. & Søgaard, O. S. (2012).
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
BMJ,
345, e5823.
https://doi.org/10.1136/bmj.e5823
Rabna, P., Andersen, A.
, Wejse, C., Oliveira, I., Gomes, V. F., Haaland, M. B., Aaby, P. & Eugen-Olsen, J. (2012).
Utility of the plasma level of suPAR in monitoring risk of mortality during TB treatment.
PLoS One,
7(8), e43933.
https://doi.org/10.1371/journal.pone.0043933Østergaard, L. J., Wejse, C., Pærregaard, A., Böttiger, B. E.
, Kallestrup, P., Andersen, B. S., Hoxer, C. S., Udsen, F. W., Kidholm, K., Reerman, D., Holt, L., Petersen, B. H., Mortensen, A. B. & Svane, S. F. (2012).
Vaccination mod rotavirus - en medicinsk teknologivurdering. In
Medicinsk Teknologivurdering Sundhedsstyrelsen.
http://sundhedsstyrelsen.dk/publ/Publ2012/06juni/MTV-RotavirusMedBilag.pdf
Yan, H.-K., Yuan, Z.-G., Song, H.-Q.
, Petersen, E., Zhou, Y., Ren, D., Zhou, D.-H., Li, H.-X., Lin, R.-Q., Yang, G.-L. & Zhu, X.-Q. (2012).
Vaccination with a DNA vaccine coding for perforin-like protein 1 and MIC6 induces significant protective immunity against Toxoplasma gondii.
Clinical and Vaccine Immunology,
19(5), 684-9.
https://doi.org/10.1128/CVI.05578-11Paredes, R., Puertas, M. C., Bannister, W., Kisic, M., Cozzi-Lepri, A., Pou, C., Bellido, R., Betancor, G., Bogner, J., Gargalianos, P., Bánhegyi, D., Clotet, B., Lundgren, J., Menéndez-Arias, L., Martinez-Picado, J. & EuroSIDA Study Group (Lars Østergaard, member) (2011).
A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Journal of Infectious Diseases,
204(5), 741-52.
https://doi.org/10.1093/infdis/jir385Reekie, J., Reiss, P., Ledergerber, B., Sedlacek, D., Parczewski, M., Gatell, J., Katlama, C., Fätkenheuer, G., Lundgren, J. D., Mocroft, A. & EuroSIDA Study Group (Lars Østergaard, member) (2011).
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
HIV Medicine,
12(5), 259-68.
https://doi.org/10.1111/j.1468-1293.2010.00877.xPetersen, TS., Andersen, SE., Gerstoft, J., Thorsteinsson, K.
, Larsen, C. S., Pedersen, G., Pedersen, C. & Obel, N. (2011).
Adherence to national guidelines for initiation of antiretroviral regimens in HIV patients: a Danish nationwide study.
British Journal of Clinical Pharmacology,
72(1), 116-24.
https://doi.org/10.1111/j.1365-2125.2011.03935.xKowalska, J. D., Mocroft, A., Ledergerber, B., Florence, E., Ristola, M., Begovac, J., Sambatakou, H., Pedersen, C., Lundgren, J. D., Kirk, O. & EuroSIDA Study Group (Lars Østergaard, member) (2011).
A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study.
HIV Clinical Trials,
12(2), 109-17.
https://doi.org/10.1310/hct1202-109Østergaard, L. J., Silfverdal, S. A., Berglund, J., Flodmark, C. E., West, C., Bianco, V., Baine, Y. & Miller, J. (2011).
A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: An open, randomised, controlled trial.
Vaccine Weekly.
https://doi.org/10.1016/j.vaccine.2011.11.051